RxDoctor Payments DataLook up a doctor →

Bolkar Sahinler, MD

Interventional Pain Medicine · Lubbock, TXNPI 1659368793

Payments from drug & device makers

$188,447in general payments, 2019–2025

Across 507 payments — averaging $371.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$173K
  • Roche Diagnostics Corporation$5K
  • Abbott$3K
  • Relievant Medsystems, Inc.$2K
  • Vertiflex, Inc.$2K
  • Boston Scientific$989
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$4,7002%
  • Travel & lodging$5,1593%
  • Food & beverage$14,2568%
  • Entertainment$500%
  • Other$164,28287%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$188,447 in reported general payments places this provider in the 95th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$499,060
Medicare patients
924
Services billed
4,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen4,235$120,852
NucyntaTapentadol Hcl33$46,491
OxycontinOxycodone Hcl77$34,359
Fentanyl272$25,193
Xtampza ErOxycodone Myristate50$24,462
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen760$23,649
Nucynta ErTapentadol Hcl19$17,124
Morphine Sulfate ErMorphine Sulfate517$14,616
Gabapentin879$13,008
Pregabalin573$12,356
Hydromorphone Hcl644$11,948
MovantikNaloxegol Oxalate20$11,419
LinzessLinaclotide19$11,228
Hydrocodone-IbuprofenHydrocodone/Ibuprofen30$7,449
Hysingla ErHydrocodone Bitartrate15$6,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Nucynta Er$357$88,077102 claims
Redhill Biopharma Inc.Movantik$18$11,41920 claims
AbbVieLinzess$676$11,22819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →